Epilepsy is a common neurological disorder affecting approximately 1% of
the population. Mutations in voltage-gated sodium channels are responsible for
several monogenic epilepsy syndromes. More than 800 mutations in the
voltage-gated sodium channel SCN1A have been reported in
patients with generalized epilepsy with febrile seizures plus and Dravet
syndrome. Heterozygous loss-of-function mutations in SCN1A
result in Dravet syndrome, a severe infant-onset epileptic encephalopathy
characterized by intractable seizures, developmental delays and increased
mortality. A common feature of monogenic epilepsies is variable expressivity
among individuals with the same mutation, suggesting that genetic modifiers may
influence clinical severity. Mice with heterozygous deletion of
Scn1a (Scn1a+/−) model a
number of Dravet syndrome features, including spontaneous seizures and premature
lethality. Phenotype severity in Scn1a+/−
mice is strongly dependent on strain background. On the 129S6/SvEvTac strain
Scn1a+/− mice exhibit no overt phenotype,
while on the (C57BL/6J × 129S6/SvEvTac)F1 strain
Scn1a+/− mice exhibit spontaneous
seizures and early lethality. To systematically identify loci that influence
premature lethality in Scn1a+/− mice, we
performed genome scans on reciprocal backcrosses. QTL mapping revealed modifier
loci on mouse chromosomes 5, 7, 8 and 11. RNA-seq analysis of strain-dependent
gene expression, regulation and coding sequence variation provided a list of
potential functional candidate genes at each locus. Identification of modifier
genes that influence survival in Scn1a+/−
mice will improve our understanding of the pathophysiology of Dravet syndrome
and may suggest novel therapeutic strategies for improved treatment of human
patients.